Home > Resources > Whitepapers > Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

MedTech, Medical

Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19

Spotlight

Invetech

For more than 30 years, Invetech has partnered with health and life science leaders around the world to co-create breakthrough solutions that millions rely on every day. Our mission is to expand the reach of next-generation healthcare by accelerating the design, engineering and manufacture of commercial-scale diagnostic products and vital cell and gene therapies.

OTHER WHITEPAPERS

The A to Z of microarrays evolution of a revolutionary solution

whitePaper | May 27, 2023

The Human Genome Project was a monumental effort over more than a decade to determine the human DNA sequence and analyze genetic variation among individuals. The hope was that, armed with this understanding, phenotypic differences would be explainable by genetic variation, and health benefits could follow.

Bispecific Antibodies Unleashed from Mechanisms to Manufacturing and Strategic Collaboration for Effective Precision Immunotherapy

whitePaper | July 13, 2023

Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising therapeutic potential such that their applicability to a variety of therapies is being explored.

Biosimilars in the United States 2023–2027

whitePaper | January 31, 2023

The first biosimilar approved under the abbreviated pathway established by the Biologics Price Competition and Innovation Act launched in the U.S. in 2015.

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Valorization of Starch to Biobased Materials

whitePaper | May 30, 2022

Many concerns are being expressed about the biodegradability, biocompatibility, and longterm viability of polymer-based substances. This prompted the quest for an alternative source of material that could be utilized for various purposes.